单药及联合辅助对患者术后肿瘤标志物SCC变化的影响

Influence of Single and Combined Adjuvant on Changes of Postoperative Tumor Marker SCC

目的分析单药辅助和联合辅助对患者术后SCC的影响。方法选择2013年1月至2017年11月收治的宫颈癌284例患者,对照组使用卡铂单药辅助治疗,研究组术前接受紫杉醇注射液联合顺铂联合辅助化疗,比较肿瘤标志物SCC变化、疗效及不良反应。结果研究组的临床疗效优于对照组(P<0.05);不良反应比较差异无统计学意义(P>0.05);术前两组患者肿瘤标志物SCC的数值比较差异无统计学意义(P>0.05),两组术后SCC数值显著优于术前,且研究组患者的下降更显著(P<0.05)。结论紫杉醇注射液联合顺铂对宫颈癌患者联合辅助治疗疗效较好,可明显改善患者术后的SCC肿瘤标志物数值。

Objective To analyze the effect of single or combined adjuvant therapy on postoperative SCC. Methods 284 patients with cervical cancer from January 2013 to November 2017 were selected. The control group was treated with carboplatin alone. The study group received paclitaxel injection combined with cisplatin combined with adjuvant chemotherapy before operation. The changes of tumor marker SCC,efficacy and adverse reaction were compared. Results The clinical effect of the study group was better than that of the control group(P<0.05). There was no significant difference in adverse reaction between groups(P>0.05). There was no significant difference in tumor marker SCC between the two groups before operation(P>0.05). The value of SCC in the two groups was significantly higher than that before operation,and the decrease of SCC in the study group was more significant(P<0.05). Conclusion Paclitaxel injection combined with cisplatin has good therapeutic effect on patients with cervical cancer and can obviously improve the tumor marker value of postoperative SCC.